Pet Cancer Therapeutics Market : Facts, Figures and Analytical Insights 2020-2026

This report researches the worldwide Pet Cancer Therapeutics market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions. This study categorizes the global Pet Cancer Therapeutics breakdown data by manufacturers, region, type and application, also analyses the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

The growing prevalence of several types of cancers in cats and dogs, as well as an increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. According to the Veterinary Cancer Society, cancer was the leading cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats, in 2017. The most common cancers in cats are leukaemia and lymphoma. Cancer is found mostly in ageing animals, but some breeds have higher rates of cancer than others. In addition to the aforementioned factor, growing pet health awareness and rise in R&D initiatives regarding pet cancer management are expected to propel market growth over the forecast period. However, side effects caused by drugs used for the treatment of pet cancers, the reluctance of pet owners to put their pet animals under medication is expected to restrain the pet cancer therapeutics market.

Get Sample Copy of this Report:
https://www.marketinsightsreports.com/reports/07202153145/pet-cancer-therapeutics-market-growth-trends-and-forecasts-2020-2025/inquiry?Mode=12&Scorce=Openpr

Top Leading Companies of Global Pet Cancer Therapeutics Market are Elanco, AdvaVet Inc., ELIAS Animal Health, Virbac, Boehringer Ingelheim GmbH (Merial), Morphogenesis Inc., Radiology Oncology Systems, Regeneus Ltd, VetDC Inc., IDvet and others.

Industry News and Developments:

July 15, 2020 — $7.6-billion Elanco deal gets FTC green light

Elanco’s acquisition of Bayer Animal Health is on track to close early August

A multibillion dollar deal 11 months in the making has received final clearance from the U.S. Federal Trade Commission (FTC). Elanco Animal Health has received unanimous approval for its $7.6-billion acquisition of Bayer’s animal health division. The decision represents the final antitrust clearance needed to complete the transaction, which is set to close at the beginning of August, Elanco says. “This approval marks the near-final step in fulfilling our vision of bringing together two dedicated animal health companies,” says the company’s president and CEO, Jeff Simmons. “As we approach closing and look toward putting our integration plans into action, I want to thank everyone who has worked so tirelessly on this transaction, especially during these challenging times.”

January 22, 2020: 2020 Startups to Watch: ELIAS Animal Health wags past milestones in cancer treatment for dogs

Hitting impactful key performance indicators after a long and complicated journey since its founding, ELIAS Animal Health is heading into the new year revenue producing and confident in goals for a $5 million funding round, said Tammie Wahaus. “I think the enthusiasm of the investors is reflective of their satisfaction with the milestones that we’ve been hitting and the opportunity that we have in front of us to have significant growth in the coming years,” said Wahaus, CEO of the biotech firm. Along with raising capital, the startup is expected to expand its team to maximize efforts to boost commercial access to its products, Wahaus said.

OLATHE, Kan., Oct. 25, 2018 -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS' Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days1). The results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019.

Key Market Trends

Cancers in Dogs are Expected to Lead the Market

Dogs get cancer at about the same rate as humans, while cats get fewer cancers. Some breeds or families of dogs have a higher incidence for developing cancer at an earlier age, but in most cases, it’s a disease found in aging animals. As per the non-profit organization FETCH a Cure, an estimated 6 million dogs were diagnosed with cancer in year 2019 across the globe. This indicates that there is a rising need for cancer treatment in dogs, which is likely to boost the demand for cancer therapeutics.In addition, the growing pet health awareness and a rise in the R&D initiatives regarding pet cancer management are expected to propel the market growth, over the forecast period. For instance, in April 2019 Elanco has signed a development and commercialization agreement with VetDC for Tanovea-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

North America Dominates the Pet Cancer Therapeutics Market

North America is expected to retain its significant market share, owing to factors, such as rising pet adoption and increasing per capita animal healthcare expenditure. In addition, the rise in the prevalence of various animal diseases and injuries has been identified as the major factor fueling market growth. Approximately, 90 million dogs are owned in the United States, as per reported by the American Pet Products Association (APPA). In addition, the data published by APPA, in 2019, stated that the total pet healthcare expenditure is estimated to be USD 75.38 billion by the end of the year, while the expenditure in 2018 was USD 72.56 billion. North America also emphasizes on establishing proper skills among veterinary practitioners. Hence, all these factors are driving the growth of the pet cancer therapeutics market in North America.

Regional Outlook of Pet Cancer Therapeutics Market report includes the following geographic areas such as: North America, Europe, China, Japan, Southeast Asia, India and ROW.

This allows an understanding of the market and benefits from any lucrative opportunities that are available. Researchers have offered a comprehensive study of the existing market scenario while concentrating on the new business objectives. There is a detailed analysis of the change in customer requirements, customer preferences, and the vendor landscape of the overall market.

Browse Full Report at:
https://www.marketinsightsreports.com/reports/07202153145/pet-cancer-therapeutics-market-growth-trends-and-forecasts-2020-2025?Mode=12&Scorce=Openpr

Following are major Table of Content of Pet Cancer Therapeutics Industry:

• Pet Cancer Therapeutics Market Sales Overview.
• Pet Cancer Therapeutics Market Sales Competition by Manufacturers.
• Pet Cancer Therapeutics Market Sales Analysis by Region.
• Pet Cancer Therapeutics Market Sales Analysis by Type.
• Pet Cancer Therapeutics Market Analysis by Application.
• Pet Cancer Therapeutics Market -Manufacturers Analysis.

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Analytical Tools: The Global Pet Cancer Therapeutics Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.
Please connect with our sales team (sales@marketinsightsreports.com).

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.